Batavia Bioservices announced its decision to change its name to Batavia Biosciences as of April 23, 2015. The change will coincide with the launch of a new website and multimedia communication strategy. Since its establishment in 2009, the company has experienced rapid growth and has established itself as a globally recognised and reliable partner for biotech companies, large pharmaceutical companies, government agencies, and academia.
Willem te Beest, vice-president of Leiden University and president of the Leiden Bio Science Park foundation, will hand over a micro-3D-portrait of the King printed by student entrepreneurs to the major of Leiden Henri Lenfernik on Kings Day 2015. This portrait of Willem-Alexander – as small as a salt crystal – produced by Leiden based Idris Solutions shows the scale on which this new technique of micro-3D-printing can work.
> Read more in Dutch
At AREA071 in Leiderdorp, the first Dutch Startup Experience will take place on the 23rd and 24th of April. Fifty students from a variety of disciplines will work in teams and address a social issue. The program, which was developed by Silicon valley entrepreneur and internationally renowned universities, is offered by Leiden University of Applied Sciences of and Leiden University. Want to know more? Check this!
> Read more in Dutch
Galapagos' JAK1 inhibitor filgotinib (GLPG0634) meets primary and other key efficacy endpoints after 12 weeks of treatment in DARWIN 1 Phase 2B studyPublished : Tuesday, April 14, 2015
The BioBusiness Masterclass is an extensive training program for entrepreneurs (to-be) in life sciences, agro-food or chemistry. The Masterclass is a hands-on program that guides your next steps in starting a business or in growing towards a management position. The 2015 edition of the BioBusiness Masterclass starts fall 2015. So, register now!
For the 7th consecutive year, Universal Biotech launches the call for proposal to valorise the most innovative projects in the healthcare industry. The Innovation Prize awards young start-ups (< 8 years) and academic research groups working on projects concerning drugs, medical devices, medical technologies and e-health solutions.
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, announced it has been granted a European patent (patent no. EP 2 155 240) for the intradermal administration of synthetic long peptides (SLP®s) based on HPV oncogenes, including its lead compound ISA101. Specifically, the patent was granted for the therapeutic use of intradermally delivered long peptides derived from the E2, E6 and/or E7 proteins of the human papillomavirus (HPV) to treat or prevent HPV-related diseases.
The Dutch Financial Times (FD) reports that BBB Therapeutics (formerly to-BBB) is starting through. Under the lead of founder Pieter Gaillard a group of investors reached an agreement with curator Marc Udink on the basic elements of the deal. The actual deal value was not published. BBB Therapeutics was perceived as promising and developed therapies for the treatment of devastating brain diseases.
Galapagos NV announced that Janssen Pharmaceutica NV and Galapagos have mutually agreed to terminate the inflammation alliance and option agreements between the companies. Galapagos views the molecules emerging from the alliance as strong additions to its growing proprietary pipeline. Among others, all rights to candidate drug GLPG1690, a selective autotaxin inhibitor, return to Galapagos. Galapagos has successfully completed a First-in-Human Phase 1 trial for GLPG1690 and is preparing a Phase 2 clinical trial in idiopathic pulmonary fibrosis (IPF).
The team of the Leiden Bio Science Park foundation is organizing another meeting for HR professionals working at Leiden Bio Science Park on April 2nd. This meeting will cover a number of topics, including what it takes for an employer to become ‘A great place to work’ - as illustrated by Pieter Salverda from DuPont. Also, Yvette Buchele will give a brief overview of Cell Signaling Technologies as a Leiden Bio Science Park company. Room for discussion and drinks is planned.
The Leiden Bio Science Park starters program is there to support science-based starters in their first steps as entrepreneurs. We act as a single point of contact for all kinds of starter topics, either providing support ourselves or setting up direct links to relevant partners. Pragmatism, personal contact and speed are central in our approach.
Want to stay informed of the Economic Agenda Leiden region? Subscribe you to the newsletter of program office Economie071. This office coordinates the implementation of the Agenda in which 13 partners are committed. It involves governments, educational institutions and the entrepreneurs of the Leiden region. Together they work on eight projects to strengthen the economy of the region.
Positive outcome of the PURETHAL® Birch RUSH study results in an approved, accelerated up-dosing regimenPublished : Tuesday, March 10, 2015
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced that its fully-owned subsidiary ISA Therapeutics B.V. has closed an R&D agreement with Japan-based Shin Nippon Biomedical Laboratories, Ltd. (SNBL) to explore a novel nasal delivery for ISA’s cervical cancer immunotherapeutic.
Tech Tour announced the opening of the call for applications for the Benelux Tech Tour which will take place in Belgium and the Netherlands May 20-21, 2015. The Tech Tour Selection Committee will choose the top 50 Emerging companies and the top 25 Growth companies from across the Benelux region and bring them together with leading European Venture Capital firms that are seeking to invest in the region. Selected Growth companies in the previous 2 editions of the Benelux Tech Tour have successfully raised over €170M in funding. Tech Tour’s partners for the event are iMinds and Startups.be who bring a wealth of experience and credibility to the organizing team.
ISA Pharmaceuticals announces start of first Phase I/II clinical trial of its SLP®-AMPLIVANT® conjugatesPublished : Thursday, February 26, 2015
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, has announced the start of an investigator-initiated Phase I/II clinical trial of a novel immunotherapeutic based on ISA Pharmaceuticals´ platform technology. The trial will be conducted by the Department of Clinical Oncology at Leiden University Medical Center in The Netherlands. The study will investigate the biological activity and safety of the compound in head and neck cancer patients who tested positive for human papilloma virus type 16 (HPV16). HPV infections, in particular HPV16, are one of the major causes of this type of cancer.
Lugus is the name of the new breeding ground for prospective entrepreneurs in the University of Leiden. In the former Chambre of Commerce site next to the Leiden train station a group of proactive students are working on their startups. In that former Chambre of Commerce building where once plenty of new companies were legally established, entrepreneurship is now flourishing once more.
The Leiden Bio Science Park newsletter is a free bimonthly email newsletter in English. The newsletter offers general life science news, news from the companies and institutions, a company profile, events and jobs.
click here to subscribe